Table 49Adverse events of sitagliptin compared with oral hypoglycemic agents

Scott, 200730Goldstein, 200631Williams-Herman, 200932Williams-Herman, 201033Scott, 200836Chan, 200837Nauck, 200734
Adverse eventS100GlipS100M1M2S100M1M2S100M1M2S100RosiS25/50GlipS/METGlip/MET
Treatment- emergent adverse events (%)
Hypoglycemia1.64a17.10.60.61.11111.11.62,2114.623.14.932.0
NauseaNRNR1.12.88.213101.13.310.411----2.62.7
VomitingNRNR0.00.01.11030.604.411----0.91.5
DiarrheaNRNR2.85.010.447124.57.712.63310.815.45.85.5
Abdominal painNRNR3.42.85.054653.86.6012.72.1
Rarer adverse events occurring with ≥4% incidence
Nasopharyngitis---------------------4.33.49.23.810.57.5
Upper respiratory tract infection---------------------4.34.67.719.2------
Influenza-----------------------------------
Headaches-----------------------------------
Urinary tract infections-------------------------10.811.55.42.7

Abbreviations: glim, glimepiride; glip, glipizide 5–20 mg/d; Glip/MET, glipizide added to metformin; M1, metformin 1000 mg/d; M2, metformin 2000 mg/d; MET, metformin; NR, not reported; pio, pioglitazone; S100, sitagliptin 100 mg daily; S/Glim, sitagliptin added to glimepiride; S/MET, sitagliptin added to metformin.

a

Note: this trial also included treatment arms: glimepiride plus metformin, glimepiride plus metformin plus sitagliptin.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.